Compare AbCellera Biologics Inc (ABCL) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Phillips 66 — how do they compare? AbCellera Biologics Inc trades at $9 (market cap $2.85B), while Phillips 66 trades at $224.36 (market cap $86.00B). The key difference: Phillips 66 is far larger — about 30.2× AbCellera Biologics Inc's market cap, and Phillips 66 pays a 2.36% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PSX | |
|---|---|---|
Market Cap | $2.85B | $86.00B |
Sector | Health | Energy |
52-Week High | $9.76 | $224.36 |
52-Week Low | $2.78 | $120.04 |
Enterprise Value | $2.45B | $102.46B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Phillips 66 (PSX) trades at $203.91, down 0.78% on the day, with a bearish technical signal but strong fundamental tailwinds from refining margins. Recent Q2 2026 earnings of $9.41 per share beat estimates, driven by high utilization and robust cash flow. The stock has support near $201 and resistance at $206, with a consensus price target of $221.92 suggesting upside potential.
Outlook is positive due to sustained refining profitability and debt reduction, but risks include volatile crude prices and geopolitical tensions. Analysts are predominantly bullish (57% buy ratings), though technical indicators warn of near-term pressure. Investors should weigh strong fundamentals against sector cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
